ACRES Commercial Realty Corp. (ACR)
$
22.97
+0.45 (1.96%)
Key metrics
Financial statements
Free cash flow per share
2.2441
Market cap
167.9 Million
Price to sales ratio
1.3446
Debt to equity
3.1858
Current ratio
2.2058
Income quality
0.7834
Average inventory
0
ROE
0.0501
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
ACRES Commercial Realty Corp., a prominent real estate investment trust (REIT), is engaged in the origination, holding, and management of commercial real estate mortgage loans and related debt investments across the United States. The company's gross profit ratio is 0.44 reflecting the efficiency of its production and sales operations. With a gross profit standing at $36,592,000.00 ACRES demonstrates its profitability from core operations. The company recorded a net income of $29,267,000.00 further showcasing its financial success. Additionally, the diluted EPS is $ 1.15 accounting for potential share dilution, while the EBITDA ratio is 1.51 highlighting operational efficiency. Formerly known as Exantas Capital Corp., it transitioned to ACRES Commercial Realty Corp. in February 2021. Incorporated in 2005 and based in Uniondale, New York, the firm invests in a variety of commercial real estate-related assets, encompassing floating and fixed-rate first mortgage loans, subordinated interests in these loans, mezzanine debt, commercial mortgage-backed securities, and more. By distributing 100% of its REIT taxable income, the company maintains its qualification for federal income tax benefits, generally avoiding federal corporate income tax liabilities. The stock of ACRES Commercial Realty Corp. is currently affordable at $ 20.95 making it suitable for budget-conscious investors. Despite its appealing pricing, the stock has a low average trading volume of 26,593.00 indicating lower market activity. With a market capitalization of $ 167,931,878.00 the company is classified as a small-cap player. It plays a key role in the REIT - Mortgage industry, thereby contributing significantly to the overall market landscape. Additionally, ACRES belongs to the Real Estate sector, where it actively drives innovation and fosters growth. The interplay of these factors positions ACRES Commercial Realty Corp. as a notable participant in its field, attracting interest from a diverse range of investors while maintaining a strategic focus on commercial real estate debt investments.
Is ACRES Commercial Realty Corp. (ACR) a good investment?
Investing in ACRES Commercial Realty Corp. (ACR) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bullish outlook. Always conduct your own research before investing.
What is ACRES Commercial Realty Corp. (ACR)'s stock forecast?
Analysts predict ACRES Commercial Realty Corp. stock to fluctuate between $14.94 (low) and $23.81 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is ACRES Commercial Realty Corp.'s market capitalization?
As of 2025-12-04, ACRES Commercial Realty Corp.'s market cap is $167,931,878, based on 7,310,922 outstanding shares.
How does ACRES Commercial Realty Corp. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, ACRES Commercial Realty Corp. has a Lower Market-Cap, indicating a difference in performance.
Does ACRES Commercial Realty Corp. pay dividends?
ACRES Commercial Realty Corp. pays dividends. The current dividend yield is 8.11%, with a payout of $0.28 per share.
How can I buy ACRES Commercial Realty Corp. (ACR) stock?
To buy ACRES Commercial Realty Corp. (ACR) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ACR. Place an order (Market, Limit, etc.).
What is the best time to invest in ACRES Commercial Realty Corp.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has ACRES Commercial Realty Corp. stock ever split?
ACRES Commercial Realty Corp.'s last stock split was 1:3 on 2021-02-17.
How did ACRES Commercial Realty Corp. perform in the last earnings report?
Revenue: $83,488,000 | EPS: $1.19 | Growth: 240%.
Where can I find ACRES Commercial Realty Corp.'s investor relations reports?
Visit https://www.acresreit.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for ACRES Commercial Realty Corp.?
You can explore historical data from here
What is the all-time high and low for ACRES Commercial Realty Corp. stock?
All-time high: $23.81 (2025-03-18) | All-time low: $6.62 (2023-10-23).
What are the key trends affecting ACRES Commercial Realty Corp. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
ACRES Commercial Realty Corp. ( ACR ) Q3 2025 Earnings Call October 30, 2025 10:00 AM EDT Company Participants Kyle K. Brengel Mark Fogel - President, CEO & Director Eldron Blackwell - CFO & Senior VP Andrew Fentress Conference Call Participants Matthew Erdner - JonesTrading Institutional Services, LLC, Research Division Christopher Muller - Citizens JMP Securities, LLC, Research Division Presentation Operator Good day, ladies and gentlemen, and welcome to the Third Quarter 2025 ACRES Commercial Realty Corp. Earnings Conference Call.
globenewswire.com
As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive or no conditioning chemotherapy
globenewswire.com
CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, will present new preclinical data for CLN-978, its novel investigational CD19xCD3 bispecific T cell engager.
globenewswire.com
KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA)
globenewswire.com
MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, in a spontaneous autoimmune disease mouse model Data support the potential of MRT-6160 to address multiple rheumatic autoimmune and inflammatory diseases, including Sjögren's disease, systemic lupus erythematosus, and rheumatoid arthritis Poster presentation on October 26th at 10:30 am CDT BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data on the potential of MRT-6160, a rationally designed molecular glue degrader (MGD) that selectively degrades VAV1, to treat multiple autoimmune and inflammatory diseases, at ACR Convergence 2025, held October 24-29 in Chicago, IL. “In a preclinical autoimmune disease model characterized by chronic inflammation, autoantibody production, and multi-organ involvement, administration of MRT-6160 resulted in broad activity across an array of disease markers, including attenuated autoantibody levels and reduced skin and kidney pathology,” said Sharon Townson, Ph.D.
globenewswire.com
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that complete data from the Phase 2b trial of rosnilimab, a pathogenic T cell depleter, in rheumatoid arthritis (RA), was accepted for a late-breaking oral presentation at American College of Rheumatology (ACR) Convergence 2025 in Chicago, IL, Oct. 24 – 29, 2025.
prnewswire.com
UNIONDALE, N.Y. , Sept. 15, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that its Board of Directors declared cash dividends on its Preferred Stock.
newsfilecorp.com
Zefiro has made a key breakthrough by successfully originating carbon credits based on confirmed emissions reductions of 92,956 metric tonnes of CO2 equivalent from a remediation project in Custer County, Oklahoma. Zefiro has also made its first delivery of carbon credits to Mercuria Energy America, LLC to fulfill a pre-sale agreement.
seekingalpha.com
ACRES Commercial Realty Corp. (NYSE:ACR ) Q2 2025 Earnings Conference Call July 31, 2025 10:00 AM ET Company Participants Andrew Dodd Fentress - Chairman of the Board Eldron C. Blackwell - CFO & Senior VP Kyle K.
prnewswire.com
UNIONDALE, N.Y. , July 16, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that it will release its results for the second quarter 2025, on Wednesday, July 30, 2025, after the market closes.
See all news
